As such, abiraterone, a novel anti-AR agent, and enzalutamide, a classic AR inhibitor, have been employed in trials for the treatment of metastatic castration resistance prostatic cancer in combination with Olaparib or Talazoparib; the overall positive results of these studies led to the recent approval of these combinations, irrespective of HR status [95,96]. The gene discussed is AR; the disease is prostate carcinoma.